- Mortality from noncancer comorbidities and advanced age is increased in the small proportion of patients with breast cancer who have COVID-19.
Why this matters
- Results are from 1 of the first large cohort studies of patients with breast cancer who have been evaluated for COVID-19.
- Close monitoring and aggressive treatment may be warranted for these patients with comorbidities and advanced age.
- Prospective cohort study; 15,600 patients with breast cancer, treated at Institut Curie hospitals, Paris.
- Patients were evaluated for COVID-19 during a 4-month period.
- Funding: Institut Curie; other university hospitals.
- 76 of 15,600 patients with breast cancer had suspected COVID-19 and were included.
- 59/76 had COVID-19 based on viral RNA testing or typical radiologic signs.
- No association was found between prior radiation therapy fields or extent of radiation therapy sequelae and the reach of lung lesions from COVID-19.
- 28/59 (47%) of patients were hospitalized.
- 6/59 patients were admitted to ICU.
- At publication, 76% were recovering or cured, 17% were still under observation, and 4/59 (6.8%) had died from COVID-19.
- All 4 deceased patients had significant noncancer comorbidities.
- Univariate analysis linked hypertension and advanced age (>70 years) to higher risk for ICU admission or death (both P<.05>
- No controls.
- Small numbers of infected patients.